- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04108325
A Phase Ib Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
A Single-Arm, Open-Label, Multi-Center, Phase Ib Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Yang Shu, MMeD
- Phone Number: 86 21-58320003
- Email: yshu@yl-pharma.com
Study Locations
-
-
Tianjin
-
Tianjin, Tianjin, China, 3000
- Recruiting
- Hematology Hospital of Chinese Academy of Medical Sciences
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Males and/or females over age 18
- Histologically or cytologically confirmed diagnosis of relapsed or refractory peripheral T cell lymphoma.
- Eastern Cooperative Oncology Group performance status of 0 to 2.
- Life expectancy of at least 3 months.
- At least one measurable lesion according to IRWG.
- Adequate organ function.
- Had anti-tumor treatments greater than or equal to 2 weeks prior to the first dose of investigational product (including TKI, chemotherapy, radiotherapy, immunotherapy and major surgery).
- Men and women of childbearing potential are willing to employ an effective method of contraception for the entire duration of study and 6 months after the last dose.
- Volunteers did not participate in other clinical trials within 1 month prior to study entry.
- Able to comply with the protocol judged by investigator.
- Provision of signed and dated, written informed consent prior to any study- specific evaluation.
Exclusion Criteria:
1. Previous treatment with any PI3K-delta ihinibitors. 2. Uncontrolled pleural effusion and ascites. 3. the dosage of steroid hormone ( prednisone equivalent ) was greater than 20mg/day, and lasted for more than 14 days. 4. Medical conditions in swallowing, malabsorption, or other chronic gastrointestinal disease that may hamper compliance and/or absorption of the investigational agent. 5. During the study period, drugs that may prolong the QT (such as anti arrhythmic drugs) could not be interrupted. 6. Evidence of central nervous system involvement of the malignancy, including invasion of brain parenchyma and meninges, or spinal cord compression. 7. Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy(such as pneumonia). 8. Active infection with hepatitis B and C virus ( Volunteers with HBsAg or HBcAb positive and HBV-DNA greater than or equal to 1000 coRpies/ml or 200IU/ml; HCV antibody and HCV-RNA positive ). 9. History of immune deficiency ( acquired or congenital ), or history of organ transplantation, or allogeneic bone marrow or hematopoietic stem cell transplantation. 10. Presence of severe or uncontrolled cardiovascular disease. 11. The baseline pregnancy test was positive in pregnant women, lactating women or fertile women. 12. According to the judgement of the investigator, there are concomitant diseases that seriously endanger the safety of patients or affect the completion of the study (such as severe hypertension, diabetes, thyroid diseases, etc.). 13. Medical history of other primary malignant tumors in the past 5 years except for the following: clinically cured cervical in situ, local basal cell carcinoma of the skin.
-
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: YY-20394
YY-20394 tablets will be given daily for 28 days in 28-day cycles until there appears evidence of progressive disease, intolerable toxicity, or the subject discontinues from the study treatment for other reasons.
|
Each treatment cycle is comprised of 28-day consecutive of YY-20394, 80mg QD (days 1 to 28).
Upon completion of each cycle, patients may continue to receive oral YY-20394 tablets if there are benefit from the treatment and the toxicity is tolerable.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ORR
Time Frame: up to 12 months
|
Objective Response Rate
|
up to 12 months
|
DCR
Time Frame: up to 12 months
|
Disease control rate
|
up to 12 months
|
Safety and Tolerability
Time Frame: up to 12 months
|
safety and tolerability of investigational product assessed as the number of participants experiencing adverse events (AEs, CTCAE5.0) or abnormalities in vital signs, laboratory tests, or electrocardiograms.
|
up to 12 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- YY-20394-004
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Relapsed or Refractory Peripheral T-Cell Lymphoma
-
Sun Yat-sen UniversityRecruitingRelapsed or Refractory Peripheral T-cell LymphomaChina
-
Dizal PharmaceuticalsCompletedRelapsed or Refractory Peripheral T Cell LymphomaKorea, Republic of, United States, China, Australia
-
AstraZenecaCompletedRelapsed/Refractory Peripheral T-cell Lymphoma | Relapsed/Refractory Classical Hodgkins LymphomaItaly, Sweden, United States, Taiwan, Korea, Republic of, United Kingdom, Australia, France, Singapore
-
Zhejiang Genfleet Therapeutics Co., Ltd.RecruitingRelapsed or Refractory Peripheral T-cell Lymphoma (PTCL)China
-
Great Novel Therapeutics Biotech & Medicals CorporationRecruitingRelapsed or Refractory Peripheral T-cell LymphomaTaiwan
-
Kura Oncology, Inc.CompletedRelapsed or Refractory Peripheral T-Cell LymphomaUnited States, Spain, Korea, Republic of
-
Samsung Medical CenterCompletedRelapsed or Refractory Peripheral T-cell LymphomaKorea, Republic of
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.UnknownRelapsed or Refractory Peripheral T-cell and NK/T-cell LymphomaChina
-
The First Affiliated Hospital of Xiamen UniversityThe First Affiliated Hospital with Nanjing Medical University; Shanxi Province... and other collaboratorsRecruitingPeripheral T Cell Lymphoma | Relapsed Peripheral T-Cell Lymphoma | Refractory T-Cell LymphomaChina
-
National Cancer Centre, SingaporeMerck Sharp & Dohme LLC; National Medical Research Council (NMRC), SingaporeNot yet recruitingRefractory Peripheral T-Cell Lymphoma | Relapsed Peripheral T-Cell LymphomaSingapore
Clinical Trials on YY-20394
-
Shanghai YingLi Pharmaceutical Co. Ltd.UnknownMantle Cell Lymphoma | Marginal Zone Lymphoma | Lymphoplasmacytic Lymphoma | Diffuse Large B Cell Lymphoma | Small Lymphocytic Lymphoma
-
Shanghai YingLi Pharmaceutical Co. Ltd.Not yet recruiting
-
Shanghai YingLi Pharmaceutical Co. Ltd.Not yet recruitingIndolent B-cell Lymphoma
-
Ruijin HospitalTianjin Medical University Cancer Institute and HospitalNot yet recruitingFocus on the Lymphoma Including B/T-cell LymphomaChina
-
Shanghai YingLi Pharmaceutical Co. Ltd.Not yet recruitingEffectiveness,Safety,Thymic Cancer
-
Shanghai YingLi Pharmaceutical Co. Ltd.UnknownLymphoma, FollicularChina
-
Shanghai YingLi Pharmaceutical Co. Ltd.RecruitingPeripheral T/NK Cell Lymphoma (R/R PTCL)United States
-
Shanghai YingLi Pharmaceutical Co. Ltd.Unknown
-
Shanghai YingLi Pharmaceutical Co. Ltd.Unknown
-
Shanghai YingLi Pharmaceutical Co. Ltd.UnknownB-cell Chronic Lymphocytic Leukemia | B-cell Lymphoma RecurrentChina